<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prophylaxis of infections in solid organ transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prophylaxis of infections in solid organ transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prophylaxis of infections in solid organ transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jay A Fishman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara D Alexander, MD, MHS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily A Blumberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila Bond, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Solid organ transplant recipients are considered to be at "high risk" for developing infection; individual risk is determined by a relationship between the epidemiologic exposures of the individual and the patient's "net state of immunosuppression" [
         <a href="#rid1">
          1,2
         </a>
         ]. The successful prevention of infection in the solid organ transplant recipient requires an understanding of these factors to develop an individualized preventive strategy. (See
         <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">
          "Evaluation for infection before solid organ transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">
          "Infection in the solid organ transplant recipient"
         </a>
         .)
        </p>
        <p>
         Epidemiologic exposures may have occurred many years before transplantation or at any point following the transplant procedure. The range of pathogens to which patients are exposed has increased as transplantation has become available to a broader range of individuals with more varied epidemiologic exposures and as transplant recipients survive longer, remaining on lifelong immunosuppression. Thus, clinicians must obtain a detailed history of encounters with potential pathogens, even if the exposure was relatively remote [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         The use of antimicrobial agents for prophylaxis varies by the disease being targeted for prevention and the nature of the recipient's risks. Strategies include universal prophylaxis and pre-emptive therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Universal prophylaxis
         </strong>
         involves giving an antimicrobial agent to all patients considered to be at increased risk for infection during a defined period. For example, in many programs
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) is given to all transplant recipients who do not have sulfa allergies for the prevention of
         <em>
          Pneumocystis
         </em>
         pneumonia which occurs in up to 10 percent of organ recipients; TMP/SMX also helps prevent infections with other pathogens, including
         <em>
          Listeria monocytogenes
         </em>
         and
         <em>
          Toxoplasma gondii
         </em>
         [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="local">
          'Pneumocystis pneumonia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pre-emptive therapy
         </strong>
         involves using sensitive assays (eg, antigen detection or nucleic acid testing) to monitor patients at predefined intervals to detect infection (eg, cytomegalovirus [CMV] deoxyribonucleic acid [DNA] in the blood or DNAemia) before infection progresses to invasive disease. A positive assay triggers the initiation of antimicrobial therapy, a reduction in the intensity of immunosuppression, and/or intensified monitoring. Pre-emptive therapy incurs extra costs for monitoring and coordination of outpatient care as well as clinical effects of episodes of viremia but reduces drug exposures and avoids some of the costs and toxicities of prophylactic antiviral therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hybrid approaches
         </strong>
         that include some period of prophylaxis and subsequent monitoring are also common for individuals at increased risk for infection or who are unable to comply with monitoring or intolerant of prophylaxis. Thus, following T cell-depleting antibody-induction therapies, many recipients receive some period of antiviral prophylaxis for CMV followed by a period of monitoring. This approach may be employed for the CMV seronegative organ recipient who receives an organ from a seropositive donor (D+/R-) or the seropositive recipient (R+).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PRETRANSPLANT PROPHYLAXIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before transplantation, it is important to establish the patient's immunization history, travel history, and prior infectious exposures to design an appropriate preventive strategy.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing for evidence of past infectious exposures is performed to detect asymptomatic infection in the transplant candidate. Some tests are recommended for all patients, while others are useful in selected patients with suggestive epidemiologic risk factors  (
         <a class="graphic graphic_table graphicRef59792" href="/z/d/graphic/59792.html" rel="external">
          table 1
         </a>
         ). Testing is required prior to transplantation for all recipients in the United States including human immunodeficiency virus (HIV) antibody/antigen assay, Hepatitis B virus (HBV) surface antigen, core antibody, and surface antibody, Hepatitis C virus (HCV) antibody, and HIV, HBV, and HCV nucleic acid testing. (See
         <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">
          "Evaluation for infection before solid organ transplantation"
         </a>
         .)
        </p>
        <p>
         Serologic testing is used as an indicator of significant past exposures, and, in some cases (eg, cytomegalovirus serostatus), the results are used to guide prophylactic strategies after transplantation. In other cases, the results are used to guide pretransplant immunizations or therapy. These issues are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">
          "Evaluation for infection before solid organ transplantation", section on 'Laboratory testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
         During the coronavirus disease 2019 (COVID-19) pandemic, routine screening of organ donors and recipients for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was recommended. Screening is typically still performed for deceased donors, most notably lung donors during bronchoalveolar lavage (BAL), and symptomatic living donors are tested. In potential recipients, COVID-19 infection and SARS-CoV-2 viral shedding must, in general, be resolved in advance of organ transplantation. Each center will determine a protocol for such potential recipients. Assays used in viral diagnosis and serologic tests for the detection of prior infection are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">
          "COVID-19: Issues related to solid organ transplantation", section on 'Pretransplantation screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Immunizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of infection through immunization is of great importance [
         <a href="#rid7">
          7,8
         </a>
         ]. Optimally, transplant candidates should be immunized before transplantation because they are less likely to mount a protective immune response once immunosuppressed following transplantation. Immunization with live virus vaccines is generally avoided post-transplant (and near to time of transplantation) as it may result in unchecked proliferation of attenuated vaccine strains. The safety and efficacy of these vaccines in selected transplant recipients is understudy [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
         Vaccine recommendations for solid organ transplant candidates and recipients are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Screening for latent tuberculosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one compilation of published cases, the incidence of tuberculosis (TB) in transplant recipients worldwide ranged from 0.35 to 15 percent, which reflected an 8- to 100-fold increased incidence over the general population in the represented countries [
         <a href="#rid10">
          10,11
         </a>
         ]. Reactivation of latent disease following immunosuppression is thought to be the dominant factor in the pathogenesis of infection in these hosts, although transmission with the allograft, nosocomial transmission, and community-acquired TB have been documented in solid organ transplant recipients. The presentation of TB in immunocompromised hosts is often atypical (eg, meningitis), emphasizing the importance of screening.
        </p>
        <p>
         Given the high morbidity associated with TB in the post-transplant setting, all patients listed for organ transplantation should undergo tuberculin skin testing (TST) or TB interferon-gamma release assays [
         <a href="#rid4">
          4,10-14
         </a>
         ]. In addition to TST, baseline chest radiographs should be obtained for an epidemiologic history suggestive of exposure to TB. For patients with uremia, liver failure, and for those who have received corticosteroids or other immunosuppressive therapies, TST must be interpreted according to the more sensitive standards developed for patients with HIV infection.
        </p>
        <p>
         T cell-based interferon-gamma release assays, such as the QuantiFERON Gold TB (QFT-G) assay, are a useful alternative to TST with a high degree of concordance between TSTs and the QFT-G assay [
         <a href="#rid15">
          15,16
         </a>
         ]. Although some studies have suggested that QFT-G correlates better with the risk of TB in immunocompromised patients than the TST, data remain limited [
         <a href="#rid15">
          15
         </a>
         ], and false-negative results have been reported for both tests [
         <a href="#rid17">
          17
         </a>
         ]. In a study of liver transplant candidates, indeterminate QFT-G results were more likely in those with more advanced liver disease [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients", section on 'Screening'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">
          "Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"
         </a>
         .)
        </p>
        <p>
         Pretransplant antituberculous prophylaxis or therapy should be provided for solid organ transplant candidates with the following specific indications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tuberculin reactivity of ≥5 mm before transplantation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of tuberculin reactivity without adequate prophylaxis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent conversion of TST to positive
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic evidence of old TB without prior prophylaxis; a chest computed tomographic scan should be performed in these patients to look for disseminated disease and to serve as a baseline study
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of inadequately treated TB
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Close contact with an individual with active pulmonary TB
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Receipt of an allograft from a donor with a history of untreated TB
        </p>
        <p>
        </p>
        <p>
         The risk of infection relates to the intensity and temporal proximity of exposure. Individuals from endemic regions for TB with positive skin tests or radiologic evidence of prior disease merit therapy. Individuals with prior Bacille Calmette-Guérin (BCG) therapy should be followed expectantly without therapy unless prior disease or recent exposure is suspected.
        </p>
        <p>
         If possible, therapy should be provided prior to transplantation. Patients may receive one of a variety of regimens for the treatment of latent TB infection [
         <a href="#rid18">
          18
         </a>
         ]. The routine use of antituberculous prophylaxis after transplantation remains controversial but is generally provided to anyone with high risk of active infection including regions with high endemicity.
        </p>
        <p>
         Treatment after transplantation is frequently compromised by drug toxicities and interactions with immunosuppressive therapies.
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         or
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         hepatotoxicity, for example, may be intolerable after liver transplantation.
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         will significantly reduce the serum level of calcineurin inhibitors and of glucocorticoids, effects that persist for several weeks after cessation of therapy. This observation suggests that treatment regimens that include rifampin should be completed two to four weeks before transplantation, whenever possible. Regimens that include the fluoroquinolones and
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         are available as alternative treatments for latent TB in organ transplant recipients; drug interactions may still occur with these alternative regimens.
        </p>
        <p>
         The evaluation and management of TB in lung transplant candidates and recipients are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3231176341">
         <span class="h2">
          Microbial colonization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assessment of microbial colonization patterns can be used to guide peritransplant prophylaxis for bacteria (eg, methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         , vancomycin- or daptomycin-resistant
         <em>
          Enterococcus
         </em>
         , carbapenem-resistant Enterobacteriaceae) [
         <a href="#rid19">
          19
         </a>
         ]. Available microbiologic data should be reviewed prior to transplantation. Some data may be available from prior microbiologic evaluations (eg, microbiology from bronchoscopic evaluations or endoscopic retrograde cholangiopancreatography [ERCP]) or prior infections (eg,
         <em>
          Clostridioides
         </em>
         [formerly
         <em>
          Clostridium
         </em>
         ]
         <em>
          difficile
         </em>
         colitis). Individuals with active chronic infections should have infecting organisms identified and susceptibility testing performed prior to transplantation to help guide peritransplant prophylaxis. (See
         <a class="local">
          'Peri-transplantation prophylaxis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H946897450">
         <span class="h2">
          Treatment of active or recurrent infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because infections are more difficult to treat following transplantation when patients are immunosuppressed, any active infection identified prior to transplantation should be treated when possible. Similarly, patients with recurrent infection or anatomic predispositions to infection (eg, recurrent aspiration or diverticulitis) may require additional care prior to transplantation.
        </p>
        <p>
         As examples, patients with recurrent
         <em>
          C. difficile
         </em>
         infection may benefit from fecal transplantation [
         <a href="#rid20">
          20-22
         </a>
         ]; patients with diverticulitis may benefit from pre-emptive surgery prior to transplantation. (See
         <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">
          "Evaluation for infection before solid organ transplantation", section on 'Active infections in the transplant candidate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          PERI-TRANSPLANTATION PROPHYLAXIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with nontransplant surgeries, solid organ transplant recipients are vulnerable to infectious complications of the surgical procedure, most commonly bacterial and fungal infections. Accordingly, perioperative antimicrobial prophylaxis should be used in accord with institutional protocols. Specific prophylactic regimens are tailored to the organ transplanted and individualized based on the recipient's unique risks.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Antibacterial prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard surgical antibiotic prophylaxis is recommended for all organ transplant procedures. The unique technical features of transplantation (vascular, ureteric, tracheal, biliary anastomoses) predispose to leaks (hematoma, bile leak, lymphocele), which are common sites of infection. As an example, the risk of peritoneal soilage is great in individuals undergoing liver transplantation with Roux-en-Y biliary drainage or with bile leaks following split or live donor liver transplants. Other risk factors for bacterial infections after liver transplantation include large-volume blood transfusions, treatment of graft rejection with glucocorticoids, and cytomegalovirus (CMV) infection [
         <a href="#rid23">
          23,24
         </a>
         ]. If the patient is colonized with methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) or vancomycin-resistant
         <em>
          Enterococcus
         </em>
         (VRE), perioperative prophylaxis should be expanded to cover the resistant organisms. Active infections must be eradicated or controlled prior to transplantation.
        </p>
        <p>
         Pretransplant colonization with multidrug-resistant organisms (MDRO), such as MDRO gram-negative bacteria, MRSA, and VRE, is associated with higher rates of peritransplant infections and recurrent infections [
         <a href="#rid25">
          25-29
         </a>
         ]; surgical complications, such as anastomotic leaks or bleeding amplify the impact of infection with such organisms. In endemic areas, a 3 to 10 percent incidence of carbapenem-resistant
         <em>
          Klebsiella pneumonia
         </em>
         infection is reported in liver, kidney, lung, or heart recipients [
         <a href="#rid25">
          25
         </a>
         ]. Carbapenem-resistant Enterobacteriaceae (CRE) carry a mortality rate of up to 40 percent once established in organ recipients [
         <a href="#rid30">
          30
         </a>
         ]. Many bacterial infections in lung transplant recipients involve the lower respiratory tract (bronchitis and pneumonia) and occur in the first two weeks post-transplant. Patients with chronic bronchiectasis and those with cystic fibrosis, who are colonized with resistant gram-negative bacteria including
         <em>
          Pseudomonas
         </em>
         and
         <em>
          Burkholderia
         </em>
         species, present a dilemma with regard to increased risk of lung transplantation. Some centers consider colonization with
         <em>
          Burkholderia cenocepacia
         </em>
         [
         <a href="#rid31">
          31
         </a>
         ] or pan-resistant
         <em>
          Pseudomonas
         </em>
         species a contraindication to transplantation.
        </p>
        <p>
         No consensus exists for the management of patients colonized with resistant gram-negative organisms during the peritransplant period. Decolonization strategies have proven effective in preventing infections in some studies [
         <a href="#rid32">
          32-35
         </a>
         ]. Peritransplant prophylaxis for MDRO merits study. Each transplant center typically develops antibiotic prophylaxis protocols based upon the susceptibility patterns of the organisms most frequently recovered at that center. Prophylactic regimens should be individualized based on recipient colonization patterns and organisms identified from donor cultures. Often these data become available only after transplantation. Serial microbiology data post-transplantation are used to refine therapy.
        </p>
        <p>
         Infections of ventricular-assist devices and chest tubes are often due to gram-positive organisms (staphylococci, enterococci) or
         <em>
          Candida
         </em>
         species, which should be identified, and susceptibility testing used to guide therapy before and after transplant. Drains and vascular access catheters must be removed as quickly as is feasible. Broad-spectrum antimicrobial prophylaxis (including antifungal agents) is generally reserved for the perioperative management of intestinal and pancreas transplants; routine use of broad-spectrum antimicrobial therapy increases the risk of
         <em>
          C. difficile
         </em>
         colitis and superinfection with resistant fungal organisms.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Antifungal prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of invasive fungal infections (IFIs) following solid organ transplantation ranges from 3 to 42 percent and varies with the organ being transplanted and the epidemiology at individual centers. In general, incidence tends to be highest in lung and liver transplant recipients and lowest in cardiac and renal transplant recipients [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         <em>
          Candida
         </em>
         and
         <em>
          Aspergillus
         </em>
         species are the leading causative agents, with the median time to onset following transplantation depending on the type of transplant [
         <a href="#rid37">
          37-41
         </a>
         ]. These infections are associated with high overall mortality rates [
         <a href="#rid42">
          42-48
         </a>
         ]. As an example, a multicenter retrospective study of 1963 cardiac, heart-lung, and lung transplant recipients in Italy reported fungal infections in 51 patients (2.6 percent) occurring at a median of 58 days post-transplantation [
         <a href="#rid49">
          49
         </a>
         ].
         <em>
          Aspergillus
         </em>
         and
         <em>
          Candida
         </em>
         spp accounted for 64 and 23 percent of the cases, respectively, with mortality rates of 29 and 33 percent, respectively.
        </p>
        <p>
         Generally, transplant centers develop institution-specific strategies for the prevention of fungal infections based on the incidence and nature of fungal infections observed at their institutions. Data support the use of prophylaxis for
         <em>
          Aspergillus
         </em>
         in liver and lung transplant recipients and for
         <em>
          Candida
         </em>
         species in lung, liver, bowel, and pancreas transplant recipients [
         <a href="#rid50">
          50-57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2647852298">
         <span class="h3">
          Targeted antifungal prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the potential for drug interactions and toxicities of antifungal agents and the risk for emergence of resistance, strategies for antifungal prophylaxis should target patients with increased risks for IFI. Targeted antifungal prophylaxis is effective for high-risk lung, pancreas, and liver transplant recipients, including those with known fungal colonization and those at increased risk for IFIs due to technical complications following surgery [
         <a href="#rid50">
          50-56
         </a>
         ]. In liver recipients, risk factors for IFI and criteria for antifungal prophylaxis vary among studies but generally include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal replacement therapy and hepatic dysfunction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bile leaks and anastomotic strictures [
         <a href="#rid50">
          50
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Living donor transplantation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large blood transfusion requirements
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged intensive care unit (ICU) stays
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CMV infection [
         <a href="#rid40">
          40,58
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional surgery post-transplant including laparotomy and retransplantation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known fungal colonization pretransplant
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged, broad-spectrum antimicrobial use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged use of total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active hepatitis C virus infection
        </p>
        <p>
        </p>
        <p>
         There are few data available on the impact of pretransplant treatment on post-transplant risk for IFI [
         <a href="#rid59">
          59,60
         </a>
         ]. In general, lung transplant recipients receive antifungal prophylaxis because of their overall high risk of IFIs [
         <a href="#rid36">
          36
         </a>
         ]. Major risk factors for IFI in lung recipients include cystic fibrosis (in the recipient), mold colonization, acute and/or chronic graft rejection, CMV infection, hypogammaglobulinemia, primary graft dysfunction, and airway stenting. (See
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         .)
        </p>
        <p>
         In pancreas transplantation, the risk of contamination (at procurement) or anastomotic leaks at exocrine drainage sites create the need for some period of anti-
         <em>
          Candida
         </em>
         prophylaxis using echinocandin or
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         [
         <a href="#rid61">
          61,62
         </a>
         ]. Enteric drainage of the pancreas predisposes to
         <em>
          Candida
         </em>
         infection. Similarly, small bowel transplants with colonic segments may transmit yeast infections.
        </p>
        <p>
         In endemic regions, long-term antifungal prophylaxis may be given to some solid-organ transplant recipients to prevent the reactivation of pulmonary and extrapulmonary disease due to
         <em>
          Coccidioides immitis and Coccidioides posadasii
         </em>
         ,
         <em>
          Histoplasma capsulatum
         </em>
         , and
         <em>
          Cryptococcus neoformans
         </em>
         . However, clinical trials supporting the routine use of antifungal prophylaxis outside of lung transplantation and in regions or institutions with high intrinsic rates of fungal infection are lacking.
        </p>
        <p>
         In programs with a high incidence of infection due to
         <em>
          Aspergillus
         </em>
         ,
         <em>
          Histoplasma
         </em>
         , or
         <em>
          Candida
         </em>
         species, both epidemiologic protection (eg, high-efficiency particulate air filtered air supply within the hospital, meticulous cleaning of operating rooms and ICUs) and antifungal prophylaxis (as appropriate to the common isolates) may be utilized [
         <a href="#rid63">
          63-66
         </a>
         ]. (See
         <a class="local">
          'Choice of regimen'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">
          "Infectious complications in liver transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         .)
        </p>
        <p>
         The approaches to antifungal prophylaxis discussed above are generally similar to available clinical practice guidelines [
         <a href="#rid36">
          36,67,68
         </a>
         ]. The 2016 Infectious Diseases Society of America and 2019 American Society of Transplantation guidelines recommend targeted prophylaxis for individuals at increased risk for
         <em>
          Aspergillus
         </em>
         infection, such as all lung transplant recipients and selected recipients of other organs who are deemed to be at increased risk based upon institutional epidemiology and individual risk factors [
         <a href="#rid67">
          67,69
         </a>
         ]. The 2015 International Society for Heart and Lung Transplantation guidelines for lung transplantation recommend anti-mold prophylaxis in lung recipients with a history of mold colonization in donor or recipient (up to 76 percent of patients with cystic fibrosis and 21 to 40 percent for other patients) or other factors outlined above [
         <a href="#rid36">
          36
         </a>
         ]. The 2019 American Society of Transplantation guidelines for the management of candidiasis in solid organ transplant recipients recommend
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         (400 mg daily) OR a lipid formulation of amphotericin B (3 to 5 mg/kg intravenously daily) as postoperative antifungal prophylaxis for liver, pancreas, and small bowel transplant recipients at high risk of IFIs [
         <a href="#rid68">
          68
         </a>
         ]. The echinocandins (
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         ) also appear to be effective for antifungal prophylaxis in solid organ transplant recipients [
         <a href="#rid62">
          62,70
         </a>
         ], and, unlike amphotericin B, are not nephrotoxic. Echinocandins are a reasonable choice for antifungal prophylaxis, although breakthrough
         <em>
          Candida
         </em>
         infections have been reported in lung recipients [
         <a href="#rid57">
          57
         </a>
         ]. Weekly administration of a lipid formulation of intravenous amphotericin B or reduced-dose lipid amphotericin B may also be an option [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H123181249">
         <span class="h3">
          Choice of regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         None of the available antifungal agents are ideal for all indications for post-transplant prophylaxis. In addition to the organ being transplanted, the selection of a specific antifungal agent should consider the epidemiology of fungal infections at the transplant center, the potential for drug interactions (both at the initiation and cessation of therapy) with the immunosuppressive regimen, and the side effect profiles of the drugs, particularly hepatotoxicity with azoles. Gaps in antifungal coverage should be noted for the echinocandins and azoles. Echinocandins have no activity against Mucorales molds or
         <em>
          Cryptococcus
         </em>
         species;
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         have no activity against Mucorales molds. Lower-risk patients at centers without significant incidence of IFI may use fluconazole or echinocandins perioperatively [
         <a href="#rid51">
          51-55
         </a>
         ].
        </p>
        <p>
         Specific antifungal prophylaxis recommendations for lung and liver transplant recipients are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">
          "Infectious complications in liver transplantation", section on 'Prevention of fungal infections'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H621499114">
         <span class="h3">
          Antifungal agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agents used for antifungal prophylaxis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         – Fluconazole appears to be safe and has not been associated with hepatotoxicity following liver transplantation; it can be used as prophylaxis against susceptible
         <em>
          Candida
         </em>
         species and reduces invasive infections in such patients [
         <a href="#rid56">
          56,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         does not have activity against filamentous fungi. In addition, some
         <em>
          Candida
         </em>
         species are intrinsically resistant (ie,
         <em>
          Candida krusei
         </em>
         ) while others have relatively high minimum inhibitory concentrations (ie,
         <em>
          Candida glabrata
         </em>
         ) to the drug. Drug interactions with calcineurin inhibitors are variable but will increase these drug levels in most patients. Similarly, serum calcineurin inhibitor levels will fall when prophylaxis is discontinued; dose readjustment is essential to prevent graft rejection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          Itraconazole
         </a>
         – Itraconazole capsules have poor oral bioavailability and should not be relied upon in the critically ill patient after transplantation. The itraconazole suspension has better oral bioavailability, but trials to date have failed to demonstrate the efficacy of the oral solution for the prevention of invasive aspergillosis [
         <a href="#rid73">
          73
         </a>
         ]. Some centers continue to use itraconazole for the prevention of fungal infection after lung transplantation [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          Itraconazole
         </a>
         levels should be obtained to assure absorption. Efficacy of the intravenous formulation as prophylaxis awaits testing in clinical trials. Significant drug interactions with calcineurin inhibitors result in levels increased two- to fourfold over baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         – Voriconazole was approved by the US Food and Drug Administration (FDA) for the treatment of aspergillosis, scedosporiosis, and fusariosis in 2002. This azole offers broader filamentous mold activity than either
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         but has no activity against the agents of mucormycosis. No multicenter trial examining the prophylactic use of voriconazole in the solid organ transplant population has been performed. Drug levels should be obtained to assure absorption. As with the other azoles, voriconazole is a significant inhibitor of the cytochrome P450 enzymes. Of note, coadministration of voriconazole and
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         is contraindicated due to these interactions [
         <a href="#rid74">
          74
         </a>
         ]. Significant drug interactions with calcineurin inhibitors result in levels three- to fivefold over baseline in most patients. Adverse effects associated with voriconazole use include dose-related hepatoxicity, QT prolongation, and increased rates of skin cancers in immunosuppressed patients [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Selected clinical effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          Posaconazole
         </a>
         – Posaconazole was approved for prophylaxis in high-risk hematopoietic cell transplantation recipients and is used for antimold prophylaxis in heart and lung recipients at some centers. Optimal use for therapy and prophylaxis is solid organ transplantation is not yet well defined. QT prolongation may be significant and may be affected by other concurrent medications. Drug levels should be obtained to assure absorption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          Isavuconazole
         </a>
         – Isavuconazole is a triazole antifungal approved in 2015 for the treatment of invasive aspergillosis and invasive mucormycosis [
         <a href="#rid76">
          76
         </a>
         ]. This agent is used for antimold prophylaxis in lung recipients at some centers. Like
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         , optimal use in therapy and prophylaxis in solid organ transplantation have not yet been defined. QT prolongation is less frequent with this agent. Drug levels should be obtained to assure absorption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amphotericin B
         </strong>
         – Lipid formulations of amphotericin B are used at some centers for the prevention of fungal infections but may be associated with nephrotoxicity, notably in individuals receiving calcineurin inhibitors or with diminished renal function at baseline. Several studies have demonstrated the failure of low-dose regimens as prophylaxis for invasive aspergillosis [
         <a href="#rid77">
          77,78
         </a>
         ], and such therapies should be used with caution.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies evaluating aerosolized amphotericin B (including lipid formulations) for
         <em>
          Aspergillus
         </em>
         prophylaxis in lung transplant recipients have demonstrated safety and efficacy for short-term prophylaxis [
         <a href="#rid57">
          57,79-83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation", section on 'Inhaled amphotericin B'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Echinocandins
         </strong>
         – There are four FDA-approved echinocandins with similar spectra of antifungal activity (
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         ). In an open-label randomized trial that compared micafungin with center-specific standard care (
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         , caspofungin) in high-risk liver transplant recipients, similar rates of clinical success (defined as absence of proven/probable IFI and no need for additional antifungals) were observed with micafungin and standard care (98.6 versus 99.3 percent) [
         <a href="#rid70">
          70
         </a>
         ]. In another study in which anidulafungin was compared with fluconazole in high-risk liver transplant recipients, the overall rate of IFIs was similar in both groups (5 versus 8 percent) [
         <a href="#rid62">
          62
         </a>
         ]. There was a trend toward a reduction in
         <em>
          Aspergillus
         </em>
         colonization or infection in the anidulafungin group compared with the fluconazole group (3 versus 9 percent). These agents are not inducers or inhibitors of the cytochrome P450 enzymes. In patients with mild and moderate hepatic impairment, caspofungin area under the curve (AUC) is increased about 20 and 75 percent, respectively; there is no clinical experience with this agent in patients with severe hepatic insufficiency.
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         moderately increases the AUC of caspofungin and elevations in hepatic transaminases were noted in healthy subjects when the drugs were administered concomitantly. In liver transplant recipients, caspofungin may increase transaminase levels with or without coadministration of calcineurin inhibitors [
         <a href="#rid84">
          84
         </a>
         ]. These drugs are available in intravenous formulations only. (See
         <a class="medical medical_review" href="/z/d/html/13945.html" rel="external">
          "Pharmacology of echinocandins and other glucan synthesis inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The pharmacology of these antifungal agents is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13945.html" rel="external">
          "Pharmacology of echinocandins and other glucan synthesis inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3072141262">
         <span class="h1">
          POST-TRANSPLANT PROPHYLAXIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following transplantation, recipients are vulnerable to nosocomial infections, especially in the early post-transplant period. Patients with prolonged hospitalizations or who require mechanical ventilation are at particularly high risk. The infections commonly encountered in the first month after transplantation are caused by the nosocomial pathogens that infect other complex postoperative patients. Ninety-five percent of these infections are due to bacterial and fungal agents. However, the difficulty in eradication of such infections is increased in the immunocompromised host.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Pneumocystis pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Pneumocystis jirovecii
         </em>
         (formerly
         <em>
          Pneumocystis carinii
         </em>
         ) is a ubiquitous organism and common fungus that is a well-known cause of pulmonary disease in the immunocompromised host [
         <a href="#rid6">
          6
         </a>
         ]. Prior to the use of
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) prophylaxis, the incidence of infection was 10 to 15 percent in most programs and was reported to be as high as 70 to 88 percent in the lung transplant population [
         <a href="#rid44">
          44,85
         </a>
         ]. The effectiveness of prophylaxis against
         <em>
          Pneumocystis
         </em>
         pneumonia (PCP) has virtually eliminated the organism as a cause of significant morbidity in solid organ transplantation [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p>
         The usual dose of TMP-SMX is one single-strength tablet a day or one double-strength tablet three to seven times a week. The distinct advantages of TMP-SMX prophylaxis include low cost, low toxicity in most individuals, and efficacy in the prevention of many common urinary, respiratory, and gastrointestinal infections as well as most, but not all, infections due to
         <em>
          Toxoplasma
         </em>
         ,
         <em>
          Listeria
         </em>
         species, and
         <em>
          Isospora belli
         </em>
         . TMP-SMX may also provide some protection against infection with
         <em>
          Nocardia
         </em>
         spp, although breakthrough infections have been reported. As an example, in a case-control study of solid organ transplant recipients with nocardiosis, 24 (69 percent) of 35 case patients were receiving TMP-SMX for PCP prophylaxis [
         <a href="#rid87">
          87
         </a>
         ]. Successful prevention of infections other than PCP requires daily dosing.
        </p>
        <p>
         Prophylaxis should be continued for six months to one year; many renal and liver programs use less. Extending the duration of PCP prophylaxis beyond one year may be warranted for lung transplant recipients, for patients receiving continued higher degrees of immunosuppression, or for those with persistent infections, such as CMV reactivation or recurrent respiratory infections [
         <a href="#rid88">
          88
         </a>
         ]. Programs with an increased incidence or clusters of PCP may want to extend routine prophylaxis.
        </p>
        <p>
         Daily TMP-SMX is preferred for PCP prophylaxis because of its broad antimicrobial protection (including
         <em>
          Toxoplasma
         </em>
         ,
         <em>
          Listeria
         </em>
         , and many
         <em>
          Nocardia
         </em>
         species), ease of administration, low cost, and tolerability [
         <a href="#rid89">
          89
         </a>
         ]. Thus, another agent (daily fluoroquinolone) must be added to
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         for antibacterial activity when desired (eg, for urinary tract infection prophylaxis in a renal transplant recipient). This may be of greatest importance in renal and lung transplant recipients where the early incidence of postoperative bacterial infections is high.
        </p>
        <p>
         History of "allergy" to TMP-SMX may be misleading, and allergy testing is often worthwhile. Sulfonamide hypersensitivity is occasionally reported as a basis for renal or liver toxicity [
         <a href="#rid90">
          90,91
         </a>
         ]. Patients with true hypersensitivity reactions to sulfa-containing medications may be given
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , inhaled
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         , or
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         as alternatives for PCP prophylaxis [
         <a href="#rid86">
          86
         </a>
         ]. Atovaquone dosage should be 1500 mg by mouth once daily, as solid organ transplant recipients receiving lower doses have been documented to have breakthrough infection [
         <a href="#rid86">
          86,92
         </a>
         ]. We generally advise patients to take atovaquone with fatty foods (eg, milk) to increase its absorption.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Toxoplasmosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Toxoplasmosis is an uncommon but highly morbid infection after transplantation. Given that cysts of
         <em>
          T. gondii
         </em>
         are commonly found in muscle tissues (as well as brain and phagocytic cells), the greatest risk for toxoplasmosis occurs after cardiac transplantation. The highest-risk group for symptomatic reactivation disease occurs in seronegative recipients of heart transplants from seropositive donors; the risk in this group in the absence of prophylaxis is approximately 50 to 75 percent [
         <a href="#rid3">
          3
         </a>
         ].
         <em>
          Toxoplasma
         </em>
         infection presents most often as myocarditis or cardiomyopathy but also as brain abscess, pneumonitis, empyema, or disseminated infection. Disease may occur at any time post-transplantation, with a median time to presentation of two months; up to 10 percent have reactivation in the first post-transplant month [
         <a href="#rid93">
          93
         </a>
         ]. Although uncommon, toxoplasmosis has also been transmitted by liver, kidney, and lung transplantation. Organ-transmitted disease is generally more severe than that due to reactivation of latent infection in the recipient. The risk of disease reactivation appears to be increased by use of lymphocyte-depleting induction therapy [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         Prevention of toxoplasmosis has not been well studied. In general, seronegative recipients of seropositive cardiac transplants receive at least 12 months of prophylaxis, although lifetime prophylaxis is preferred at many centers [
         <a href="#rid95">
          95
         </a>
         ]. One retrospective study suggests that TMP-SMX at a dose of one double-strength tablet three times per week is sufficient for both
         <em>
          Pneumocystis
         </em>
         and
         <em>
          Toxoplasma
         </em>
         prevention in cardiac transplant recipients [
         <a href="#rid96">
          96
         </a>
         ]. Other centers use lower-dose regimens or add
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         to TMP-SMX in high-risk (donor
         <em>
          Toxoplasma
         </em>
         seropositive and recipient seronegative) combinations [
         <a href="#rid97">
          97,98
         </a>
         ]. Lower-dose regimens provide less effective protection in such combinations, notably in seronegative cardiac transplant recipients from endemic regions (eg, France, the Caribbean islands) [
         <a href="#rid3">
          3
         </a>
         ]. The risk of disease in seropositive recipients of heart transplants from seropositive donors is uncertain, but lifetime prophylaxis with at least one single-strength tablet of TMP-SMX daily may be beneficial.
        </p>
        <p>
         Most alternative regimens (
         <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">
          sulfadiazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         or
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          primaquine
         </a>
         ) have not been well studied in high-risk transplant populations. Atovaquone or dapsone alone have been effective for prevention of
         <em>
          Pneumocystis
         </em>
         and
         <em>
          Toxoplasma
         </em>
         . Breakthrough infections have been observed with dapsone at doses of 50 mg daily, and 100 mg doses may be preferred; testing for glucose-6-phosphate dehydrogenase deficiency is required [
         <a href="#rid3">
          3
         </a>
         ]. The clindamycin-pyrimethamine regimen has also been used successfully as an alternative if intolerant of TMP-SMX.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Streptococcus pneumoniae
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunocompromised individuals have a high incidence of infection due to
         <em>
          Streptococcus pneumoniae
         </em>
         with diminished susceptibility to penicillin; many of these isolates are also resistant to TMP-SMX. Thus, transplant candidates should receive pneumococcal vaccination prior to transplant surgery unless they were vaccinated previously based upon the underlying illness, such as chronic pulmonary disease. Specific recommendations for pneumococcal vaccination in solid organ transplant candidates and recipients are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients", section on 'Pneumococcus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Viral infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Viral infections are among the most common complications of immune suppression after solid organ transplantation. The use of antiviral agents should be linked to the intensity of immune suppression and to the risk of the individual for disease.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Influenza
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccination remains the primary method of preventing and controlling influenza and continual changes in viral antigens necessitates annual revision and administration of the influenza vaccine [
         <a href="#rid99">
          99,100
         </a>
         ]. The intramuscular
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         should be given to solid organ transplant recipients. The intranasal live-attenuated influenza vaccine should
         <strong>
          not
         </strong>
         be given to solid organ transplant recipients. (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients", section on 'Influenza'
         </a>
         .)
        </p>
        <p>
         Antiviral prophylaxis is indicated under certain circumstances, such as in solid organ transplant recipients who have been exposed to an individual with suspected or confirmed influenza infection. Specific recommendations regarding antiviral prophylaxis are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7017.html" rel="external">
          "Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Cytomegalovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytomegalovirus (CMV) is the most common opportunistic pathogen following solid organ transplantation and is an important cause of morbidity and mortality. CMV may be acquired from the donated allograft, blood products transfused from a seropositive donor, or reactivation of endogenous virus. Once CMV infection is acquired, it persists as a latent infection for the lifetime of the host.
        </p>
        <p>
         Most CMV disease occurs between one and four months after transplantation in the absence of antiviral prophylaxis. Increasingly, CMV disease is recognized later, in the period following cessation of prophylaxis. Patients at highest risk for CMV disease are those who are seronegative for CMV (immunologically naive) and receive an allograft from a seropositive donor (D+/R-) and those with latent CMV infection who require treatment with antilymphocyte antibodies as a part of induction therapy or following intensification of immunosuppression for graft rejection. Asymptomatic infection is common in both the D+/R- combination and seropositive recipients [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         Universal prophylaxis with
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         is a common approach to prevention of CMV reactivation in at-risk patients (eg, CMV-seropositive recipients and recipients with CMV-seropositive donors, notably after T-lymphocyte depletion). The duration of antiviral therapy generally ranges from 3 to 12 months and often depends on the type of organ transplanted, the specific risk status of patient, and individual institutional practice [
         <a href="#rid101">
          101,102
         </a>
         ].
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          Letermovir
         </a>
         prophylaxis has also been shown to be effective in preventing CMV disease and is a reasonable option for patients who cannot tolerate valganciclovir or ganciclovir [
         <a href="#rid103">
          103,104
         </a>
         ]. In a phase-3 randomized controlled trial of over 500 D+/R- renal transplant recipients, letermovir prophylaxis was noninferior to valganciclovir prophylaxis for prevention of CMV disease through 52 weeks post-transplant (10.4 versus 11.8 percent, -1.4 percent difference, 95% CI -6.5 to 3.8 percent) but had a significantly lower rate of leukopenia or neutropenia (26 versus 64 percent) compared with valganciclovir [
         <a href="#rid103">
          103
         </a>
         ]. If letermovir is used, a second drug is required to prevent other herpesviruses (HSV, VZV). Many transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations; this approach may be as effective as universal prophylaxis [
         <a href="#rid102">
          102
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">
          "Prevention of cytomegalovirus infection in lung transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">
          "Infectious complications in liver transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">
          "Infectious complications in liver transplantation", section on 'Cytomegalovirus'
         </a>
         .)
        </p>
        <p>
         The efficacy of targeted anti-CMV prophylaxis in patients at highest risk for CMV reactivation (ie, CMV-seronegative recipients with CMV-seropositive donors) is well documented [
         <a href="#rid101">
          101,105,106
         </a>
         ]. A systematic review of 19 randomized controlled trials of CMV prophylaxis in 1981 solid organ transplant recipients demonstrated the following [
         <a href="#rid105">
          105
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Compared with placebo, prophylaxis with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         , or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         significantly reduced the risks of CMV disease (relative risk 0.42, 95% CI 0.34-0.52), CMV infection (relative risk 0.61, CI 0.48-0.77), and all-cause mortality (relative risk 0.63, CI 0.43-0.92). The reduction in mortality was primarily due to lower mortality from CMV disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For CMV-related disease and mortality, the relative benefits of
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         , high-dose
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         , and
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         were consistent across recipients of heart, kidney, and liver transplants and occurred in both CMV-positive and CMV-negative recipients of seropositive organs. These results were irrespective of the type of immunosuppression given. No conclusions could be drawn for CMV-negative recipients of CMV-negative organs (D-/R-). Patients considered at lower risk for CMV infection (D-/R-) should receive antiviral prophylaxis for herpes simplex virus and varicella-zoster virus with acyclovir, valacyclovir, or
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the subset of direct comparison treatment trials,
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         was more effective than
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ; high-dose
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         and intravenous ganciclovir were as effective as oral ganciclovir.
        </p>
        <p>
        </p>
        <p>
         A subsequent meta-analysis of 17 universal prophylaxis trials and 9 pre-emption trials demonstrated that both prophylaxis strategies were equally effective in reducing the incidence of CMV disease [
         <a href="#rid107">
          107
         </a>
         ]. However, only universal prophylaxis affected patient survival and reduced graft rejection and reduced the incidence of post-transplant opportunistic infections and post-transplant lymphoproliferative disorder (PTLD) [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         and intravenous
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         treatment are associated with similar long-term outcomes in solid organ transplant recipients with CMV syndrome and tissue-invasive CMV disease based on randomized trials in adult renal, liver, heart, and lung transplant recipients [
         <a href="#rid108">
          108,109
         </a>
         ]. Thus, these are the preferred drugs for CMV prophylaxis. High-dose oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         have also been used successfully in some centers. However, the oral bioavailability of these drugs is limited, the required pill burden is high, and efficacy data supporting their use are limited.
        </p>
        <p>
         Issues related to CMV prophylaxis in specific transplant settings are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">
          "Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">
          "Prevention of cytomegalovirus infection in lung transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">
          "Infectious complications in liver transplantation", section on 'Cytomegalovirus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Epstein-Barr virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epstein-Barr virus (EBV) is associated with PTLD. PTLD occurs in approximately 1 percent of transplants and ranges in severity from "benign" polyclonal lymphocytosis to highly malignant lymphomas. The optimal strategy for the prevention of PTLD has not been established, although lesser degrees of immunosuppression appear to lower the risk. Excess rates of PTLD have been observed with
         <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">
          belatacept
         </a>
         maintenance immunosuppression, notably in EBV seronegative recipients and children. Routine monitoring should be performed for higher risk patients (D+/R- for EBV and all children). (See
         <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">
          "Treatment and prevention of post-transplant lymphoproliferative disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2800640771">
         <span class="h3">
          Herpes simplex and varicella-zoster
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are not receiving
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         CMV prophylaxis (ie, patients who are seronegative for CMV and received an allograft from a CMV-seronegative donor) should receive prophylaxis against herpes simplex virus and varicella-zoster virus during the first three to six months after transplantation and during periods of lymphodepletion for treatment of rejection. Herpes zoster vaccination is recommended pretransplant, notably in those at greatest risk for zoster and for post-herpetic neuralgia. An adjuvanted subunit vaccine is available for use in transplant recipients. Newer anti-CMV agents (ie,
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          letermovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="134463" href="/z/d/drug information/134463.html" rel="external">
          maribavir
         </a>
         ) lack activity against HSV and VZV. (See
         <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">
          "Vaccination for the prevention of shingles (herpes zoster)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Hepatitis B virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hepatitis B virus vaccine is recommended for all individuals prior to transplantation. Accelerated schedules for vaccination have been developed for healthy travelers but do not appear to produce an adequate immune response in transplant candidates [
         <a href="#rid110">
          110,111
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients", section on 'Hepatitis B'
         </a>
         .)
        </p>
        <p>
         Among infected patients, hepatitis B virus (HBV) can be reactivated after transplantation. Immunosuppression can amplify HBV DNA, and steroid therapy may have a direct stimulatory effect on an enhancer region of the viral genome [
         <a href="#rid112">
          112,113
         </a>
         ]. This issue is particularly important in two settings: liver transplant recipients, in whom the graft is the primary site of HBV infection, and in renal transplant recipients, as many chronic dialysis patients are hepatitis B surface antigen (HBsAg) positive.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among liver transplant recipients, preventive therapy is given to reduce the risk of reinfection of the graft. Ideally, HBV-infected recipients should be on a nucleotide analogue reverse-transcriptase inhibitor with an undetectable or unquantifiable viral load prior to transplant. (See
         <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">
          "Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient is on tenofovir or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         prior to transplantation and has experienced effective HBV suppression, the pretransplant antiviral agent should be continued after transplantation. If the recipient is
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         experienced, tenofovir should be used due to the high rate of entecavir resistance in lamivudine-experienced patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with renal insufficiency,
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         is generally preferred over tenofovir. Concerns among renal transplant recipients are deterioration of the liver and worse renal allograft survival. (See
         <a class="medical medical_review" href="/z/d/html/7354.html" rel="external">
          "Kidney transplantation in adults: Hepatitis B virus infection in kidney transplant recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Transmission of HBV may occur with HBsAg-positive donors and in livers from donors with documented anti-hepatitis B core antibody. A review from the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database identified 23 liver transplants from isolated anti-hepatitis B core antigen (anti-HBc)-positive donors [
         <a href="#rid114">
          114
         </a>
         ]. Eighteen developed HBV infection compared with only 3 of 651 from anti-HBc-negative donors. (See
         <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">
          "Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients", section on 'Strategies to prevent HBV reinfection'
         </a>
         .)
        </p>
        <p>
         Transmission of HBV is uncommon when kidneys from anti-HBc-positive donors are used in this setting, and these donor organs are frequently transplanted to expand the pool of available kidneys, hearts, and lungs [
         <a href="#rid115">
          115
         </a>
         ]. All recipients should be immunized against HBV prior to transplantation.
        </p>
        <p>
         Given the availability of vaccination and effective therapies for HBV, transplantation of organs from HBV-infected donors may be considered on an individual basis. These donors are generally not viremic but are anti-HB core antibody positive.
        </p>
        <p class="headingAnchor" id="H296496190">
         <span class="h1">
          OTHER CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1522505229">
         <span class="h2">
          Hepatitis C virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the approval of interferon-free, direct-acting antiviral drug regimens (DAA) for treatment of hepatitis C virus (HCV), transplant physicians have greater flexibility in the timing of treatment of hepatitis C-infected patients before or after solid organ transplantation [
         <a href="#rid116">
          116-119
         </a>
         ]. Use of HCV-seropositive donor organs to expand the donor pool is routine; use of HCV-viremic donors is increasing, including in uninfected recipients. Decisions regarding the timing of DAA therapy relate to the status and progression of the disease in the individual, financial considerations, and any potential effect of improved clinical status and Model for End-Stage Liver Disease score on transplant listing [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">
          "Overview of the management of chronic hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2665505200">
         <span class="h2">
          HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV infection of recipients is not a contraindication to solid organ transplantation and outcomes are excellent [
         <a href="#rid121">
          121,122
         </a>
         ]. Increasingly, HIV-infected individuals are considered as donors for HIV-infected recipients, generally under research protocols. The care of HIV-infected and coinfected recipients (eg, HIV and HCV infected) requires expertise in the management of drug interactions among the drugs required for maintenance of immunosuppression and antiviral therapy in the post-transplant period. In general, stable antiretroviral regimens with omission of protease inhibitors is preferred to limit interactions with the calcineurin inhibitors [
         <a href="#rid121">
          121
         </a>
         ]. The optimal immunosuppressive regimens for maintenance therapy are under investigation. (See
         <a class="medical medical_review" href="/z/d/html/7332.html" rel="external">
          "Kidney transplantation in adults: Kidney transplantation in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1641141175">
         <span class="h2">
          Severe acute respiratory syndrome coronavirus 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to coronavirus disease 2019 in solid-organ transplantation are discussed separately. Vaccination should be completed if possible prior to transplantation. (See
         <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">
          "COVID-19: Issues related to solid organ transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H92216833">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117424.html" rel="external">
          "Society guideline links: Infections in solid organ transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1725996859">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of infection is high
         </strong>
         – Solid organ transplant recipients are at "high risk" for developing infection; individual risk is determined by a relationship between the epidemiologic exposures of the individual and the patient's "net state of immunosuppression." (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretransplant evaluation
         </strong>
         – Before transplantation, it is important to establish the patient's immunization history, travel history, and prior infectious exposures to design an appropriate preventative strategy. Evaluation typically focuses on laboratory testing for past infectious exposures  (
         <a class="graphic graphic_table graphicRef59792" href="/z/d/graphic/59792.html" rel="external">
          table 1
         </a>
         ), screening for latent tuberculosis, reviewing microbiologic records, and administering vaccines when appropriate. (See
         <a class="local">
          'Pretransplant prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identification of infection prior to transplant
         </strong>
         – Because infections are more difficult to treat following transplantation when patients are immunosuppressed, any active infection identified prior to transplantation should be treated when possible. Surgical or other procedures may also be warranted for those with recurrent infections or anatomic predispositions to infections. (See
         <a class="local">
          'Treatment of active or recurrent infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peritransplant prophylaxis
         </strong>
         – At the time of transplantation, solid organ transplant recipients are vulnerable to infectious complications of the surgical procedure, most commonly bacterial and fungal infections. Peritransplantation prophylaxis is typically tailored according to the organ transplanted and may need to be further individualized based on the recipient's unique risks. (See
         <a class="local">
          'Peri-transplantation prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-transplant prophylaxis
         </strong>
         – Following transplantation, prophylactic strategies vary by the specific disease being prevented and the nature of the recipient's risks. Strategies include universal, targeted, and pre-emptive prophylaxis (see
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Post-transplant prophylaxis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pneumocystis prophylaxis
         </strong>
         –
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) is given universally to all transplant recipients who do not have sulfa allergies for the prevention of
         <em>
          Pneumocystis
         </em>
         pneumonia. TMP-SMX also protects against
         <em>
          Listeria monocytogenes, Toxoplasma gondii,
         </em>
         and other potential pathogens, although efficacy against pathogens other than
         <em>
          Pneumocystis
         </em>
         varies with dose. (See
         <a class="local">
          'Pneumocystis pneumonia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antifungal and antiviral prophylaxis
         </strong>
         – Antifungal and antiviral prophylaxis is individualized (targeted) to patients considered at the greatest risk. In programs with a high incidence of infection due to
         <em>
          Aspergillus
         </em>
         ,
         <em>
          Histoplasma
         </em>
         , or
         <em>
          Candida
         </em>
         species, both epidemiologic protection (eg, high-efficiency particulate air filtered air supply within the hospital) and antifungal prophylaxis (as appropriate to the isolates) may be utilized. (See
         <a class="local">
          'Antifungal prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CMV prophylaxis
         </strong>
         – Universal prophylaxis with
         <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">
          valganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         , or
         <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">
          letermovir
         </a>
         is typically given to patients at greatest risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy depends on the organ transplanted, the risk status of the patient, and individual institutional practice. Many transplant centers prefer to use a pre-emptive approach (eg, weekly CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations (See
         <a class="local">
          'Cytomegalovirus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Herpes simplex virus and varicella-zoster virus prophylaxis
         </strong>
         – Patients who are not receiving CMV prophylaxis should receive prophylaxis against herpes simplex virus and varicella-zoster virus during the first three to six months after transplantation and during periods of intensification of immunosuppression for treatment of rejection. (See
         <a class="local">
          'Herpes simplex and varicella-zoster'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Screening for EBV reactivation
         </strong>
         – Because there is no effective antiviral prophylactic therapy for Epstein-Barr virus (EBV) reactivation, high-risk patients (eg, all children and EBV-seronegative recipients who receive organs from seropositive donors) should be monitored for reactivation at routine intervals and evaluated for evidence of post-transplant lymphoproliferative disease if reactivation occurs. (See
         <a class="local">
          'Epstein-Barr virus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vaccination
         </strong>
         – Vaccination remains the primary method for preventing influenza (
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         ), pneumococcal, and hepatitis B infections. Live vaccines should generally be avoided in immunosuppressed hosts. For patients with known hepatitis B infections, preventive treatment options are available. (See
         <a class="local">
          'Hepatitis B virus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H256802601">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Infection in Organ Transplantation. Am J Transplant 2017; 17:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Pneumocystis jiroveci. Semin Respir Crit Care Med 2020; 41:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawano Y, Suzuki M, Kawada J, et al. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine 2015; 33:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer SA, Avery RK, AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9 Suppl 4:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012; 40:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SH, Lee SO, Park IA, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis 2010; 12:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SY, Jung GS, Kim SK, et al. Comparison of the tuberculin skin test and interferon-γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013; 41:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel O, Kumar D. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Rev Mol Diagn 2008; 8:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7:2797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornum M, Mortensen KL, Kamper AL, Andersen AB. Limitations of the QuantiFERON-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patients. Eur J Intern Med 2008; 19:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 69:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mularoni A, Bertani A, Vizzini G, et al. Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria. Am J Transplant 2015; 15:2674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One 2015; 10:e0124483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant 2014; 14:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng YW, Phelps E, Ganapini V, et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019; 19:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 58:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bert F, Larroque B, Dondero F, et al. Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients. Transpl Infect Dis 2014; 16:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Nadales E, Gutiérrez-Gutiérrez B, Natera AM, et al. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. Am J Transplant 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taimur S, Pouch SM, Zubizarreta N, et al. Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes. Clin Transplant 2021; 35:e14239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003; 5:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson K, Boucher HW. Editorial commentary: imminent challenges: carbapenem-resistant enterobacteriaceae in transplant recipients and patients with hematologic malignancy. Clin Infect Dis 2014; 58:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziakas PD, Pliakos EE, Zervou FN, et al. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant 2014; 14:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garzoni C, Vergidis P, AST Infectious Diseases Community of Practice. Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh N, Squier C, Wannstedt C, et al. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol 2006; 27:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy CJ, Bartsch SM, Nguyen MH, et al. A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients. Eur J Clin Microbiol Infect Dis 2014; 33:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husain S, Sole A, Alexander BD, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. J Heart Lung Transplant 2016; 35:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz P, Rodríguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004; 4:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA, Gonzalez RG, Branda JA. Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation. N Engl J Med 2008; 358:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavaldà J, Meije Y, Fortún J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 Suppl 7:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993; 153:2010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer JR, Tullis DE, Grossman RF, et al. Infectious complications following isolated lung transplantation. Chest 1992; 101:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eschenauer GA, Kwak EJ, Humar A, et al. Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant 2015; 15:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation 2013; 96:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San-Juan R, Aguado JM, Lumbreras C, et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation 2011; 92:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah T, Lai WK, Gow P, et al. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 2005; 7:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley S, Huckabee C, Pappas PG, et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; :CD004291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker AW, Maziarz EK, Arnold CJ, et al. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. Clin Infect Dis 2020; 70:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation--a world-wide survey. Am J Transplant 2011; 11:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9:2085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaikh SA, Zimmerman A, Nolan A, et al. The incidence of fungal infections in pancreas transplant recipients in the absence of systemic antifungal prophylaxis. Clin Transplant 2019; 33:e13691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant 2014; 14:2758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslam S, Rotstein C, AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis 2015; 60:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannella M, Ercolani G, Cristini F, et al. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial. Transplantation 2015; 99:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28:250.
          </a>
         </li>
         <li class="breakAll">
          Vfend. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021266s032lbl.pdf (Accessed on May 19, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31:694.
          </a>
         </li>
         <li class="breakAll">
          CRESEMBA Package Insert. US Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf (Accessed on August 28, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorf T, Braun F, Rüchel R, et al. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999; 42:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peghin M, Monforte V, Martin-Gomez MT, et al. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation. Transpl Int 2016; 29:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huggins JP, Pease R, Stanly K, et al. Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients. Antimicrob Agents Chemother 2022; 66:e0028322.
          </a>
         </li>
         <li class="breakAll">
          CANCIDAS. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21227s015lbl.pdf (Accessed on May 19, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MR, Stoehr C, Lewiston NJ, et al. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long? Transplantation 1992; 53:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan DA, Knowles SR, Shear NH. Sulfonamide Hypersensitivity: Fact and Fiction. J Allergy Clin Immunol Pract 2019; 7:2116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad GVR, Beckley J, Mathur M, et al. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect Dis 2019; 19:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004; 38:e76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derouin F, Pelloux H, ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008; 14:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallino A, Maggiorini M, Kiowski W, et al. Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis 1996; 15:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2023; 42:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baden LR, Katz JT, Franck L, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation 2003; 75:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wreghitt TG, Gray JJ, Pavel P, et al. Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients. Transpl Int 1992; 5:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz P, Arencibia J, Rodríguez C, et al. Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients. Clin Infect Dis 2003; 36:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin Infect Dis 2010; 23:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helanterä I, Anttila VJ, Lappalainen M, et al. Outbreak of Influenza A(H1N1) in a Kidney Transplant Unit-Protective Effect of Vaccination. Am J Transplant 2015; 15:2470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018; 102:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA 2023; 330:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winstead RJ, Kumar D, Brown A, et al. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction. Transpl Infect Dis 2021; 23:e13570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc 1998; 30:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engler SH, Sauer PW, Golling M, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madayag RM, Johnson LB, Bartlett ST, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 2012; 60:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrault NA, Stock PG. Management of hepatitis C in kidney transplant patients: on the cusp of change. Am J Transplant 2014; 14:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malinis M, Boucher HW, AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020; 71:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seem DL, Lee I, Umscheid CA, et al. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013; 128:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumberg EA, Rogers CC, AST Infectious Diseases Community of Practice. Human immunodeficiency virus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1408 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Infection in solid-organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28117944" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Infection in Organ Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8747777" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pneumocystis carinii and parasitic infections in transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827281" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9593116" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevention of infection due to Pneumocystis carinii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32000290" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pneumocystis jiroveci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31002409" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25665961" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20070698" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Screening of donor and recipient prior to solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496318" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318676" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Performance of tests for latent tuberculosis in different groups of immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20113458" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22802098" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Comparison of the tuberculin skin test and interferon-γrelease assay for the diagnosis of latent tuberculosis infection before kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18598104" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17941955" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18249311" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Limitations of the QuantiFERON-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32053584" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25981339" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25886133" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24433460" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30085388" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494905" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8409334" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24463280" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24330161" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Risk factors associated with preoperative fecal carriage of extended-spectrumβ-lactamase-producing Enterobacteriaceae in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31891235" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33527453" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14617299" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24463279" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Editorial commentary: imminent challenges: carbapenem-resistant enterobacteriaceae in transplant recipients and patients with hematologic malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18318775" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25040438" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23464998" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16465627" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24500598" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26970469" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20218876" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15937763" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15023157" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403769" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810152" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Invasive fungal infections in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7556225" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Risk factors for systemic fungal infections in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8507760" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Fungal infections in solid-organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2189664" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Infectious complications in pulmonary allograft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8357286" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Infectious complications in heart-lung transplantation. Analysis of 200 episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1555420" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Infectious complications following isolated lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8016481" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Infection after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10987719" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10919584" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25359455" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Targeted versus universal antifungal prophylaxis among liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16426325" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23842191" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21709604" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16390401" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144094" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Outcomes of antifungal prophylaxis in high-risk liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15266524" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Antifungal agents for preventing fungal infections in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30801642" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9274893" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21272239" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Antifungal prophylaxis in lung transplantation--a world-wide survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19645709" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31400149" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The incidence of fungal infections in pancreas transplant recipients in the absence of systemic antifungal prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25376267" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624465" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Treatment of infection due to Pneumocystis carinii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8747778" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Fungal infections in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077723" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Risk factors for invasive fungal infections complicating orthotopic liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7535482" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31155770" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30900296" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25520332" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25531982" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577295" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10064240" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10064240" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22484291" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22484291" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1569339" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10394848" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9123449" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11744410" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502995" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26339864" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35506698" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35506698" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1549851" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565082" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prevention of infection caused by Pneumocystis carinii in transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17443467" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10064238" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489347" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31495421" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Sulfonamide Hypersensitivity: Fact and Fiction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30953458" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15095235" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19018809" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Prevention of toxoplasmosis in transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8793397" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Toxoplasmosis in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37080658" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12589155" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1418309" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12652396" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20581671" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Influenza, including the novel H1N1, in organ transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25943587" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Outbreak of Influenza A(H1N1) in a Kidney Transplant Unit-Protective Effect of Vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817026" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29596116" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37279999" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33469975" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15964447" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365468" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16941368" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19422345" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17640310" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9595103" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Accelerated schedule of hepatitis B vaccination in liver transplant candidates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11338063" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7601429" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3201757" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9352871" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9422420" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22560841" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25307029" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Management of hepatitis C in kidney transplant patients: on the cusp of change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30900327" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816111" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23814319" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23465009" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Human immunodeficiency virus in solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21083386" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Outcomes of kidney transplantation in HIV-infected recipients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
